SG11201504883PA - Peptides as oxytocin agonists - Google Patents

Peptides as oxytocin agonists

Info

Publication number
SG11201504883PA
SG11201504883PA SG11201504883PA SG11201504883PA SG11201504883PA SG 11201504883P A SG11201504883P A SG 11201504883PA SG 11201504883P A SG11201504883P A SG 11201504883PA SG 11201504883P A SG11201504883P A SG 11201504883PA SG 11201504883P A SG11201504883P A SG 11201504883PA
Authority
SG
Singapore
Prior art keywords
peptides
oxytocin agonists
oxytocin
agonists
Prior art date
Application number
SG11201504883PA
Other languages
English (en)
Inventor
Caterina Bissantz
Konrad Bleicher
Christophe Grundschober
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11201504883PA publication Critical patent/SG11201504883PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/16Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201504883PA 2012-12-21 2013-12-17 Peptides as oxytocin agonists SG11201504883PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12199012 2012-12-21
PCT/EP2013/076783 WO2014095773A1 (en) 2012-12-21 2013-12-17 Peptides as oxytocin agonists

Publications (1)

Publication Number Publication Date
SG11201504883PA true SG11201504883PA (en) 2015-07-30

Family

ID=47471593

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201504883PA SG11201504883PA (en) 2012-12-21 2013-12-17 Peptides as oxytocin agonists

Country Status (34)

Country Link
US (1) US9868766B2 (zh)
EP (1) EP2935312B1 (zh)
JP (1) JP6067878B2 (zh)
KR (1) KR101819804B1 (zh)
CN (1) CN104870466B (zh)
AR (1) AR094225A1 (zh)
AU (1) AU2013363768B2 (zh)
BR (1) BR112015014010A2 (zh)
CA (1) CA2895150C (zh)
CL (1) CL2015001724A1 (zh)
CR (1) CR20150271A (zh)
DK (1) DK2935312T3 (zh)
EA (1) EA026687B1 (zh)
ES (1) ES2690317T3 (zh)
HK (1) HK1208477A1 (zh)
HR (1) HRP20181569T1 (zh)
HU (1) HUE039848T2 (zh)
IL (1) IL239519A (zh)
LT (1) LT2935312T (zh)
MA (1) MA38272A1 (zh)
MX (1) MX358684B (zh)
MY (1) MY176398A (zh)
NZ (1) NZ708175A (zh)
PE (1) PE20151446A1 (zh)
PH (1) PH12015501145A1 (zh)
PL (1) PL2935312T3 (zh)
PT (1) PT2935312T (zh)
RS (1) RS57690B1 (zh)
SG (1) SG11201504883PA (zh)
SI (1) SI2935312T1 (zh)
TW (1) TWI558726B (zh)
UA (1) UA119034C2 (zh)
WO (1) WO2014095773A1 (zh)
ZA (1) ZA201504186B (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
MY176398A (en) 2012-12-21 2020-08-05 Hoffmann La Roche Peptides as oxytocin agonists
EA201590943A1 (ru) 2012-12-21 2016-01-29 Алиос Биофарма, Инк. Замещенные нуклеозиды, нуклеотиды и их аналоги
KR102116107B1 (ko) 2013-12-30 2020-05-28 삼성디스플레이 주식회사 표시 장치
USRE49816E1 (en) 2014-01-10 2024-01-30 Cornell University Dipeptides as inhibitors of human immunoproteasomes
WO2015185467A1 (en) 2014-06-03 2015-12-10 F. Hoffmann-La Roche Ag Peptides as oxytocin agonists
EP3521285A1 (en) 2014-06-17 2019-08-07 Pfizer Inc Substituted dihydroisoquinolinone compounds
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
SI3177635T1 (sl) * 2014-08-07 2019-01-31 F. Hoffmann-La Roche Ag Postopki za pripravo analogov oksitocina
JP6758282B2 (ja) * 2014-08-18 2020-09-23 コーネル・ユニバーシティーCornell University ヒト免疫プロテアソーム阻害剤としてのジペプチド模倣薬
LT3666258T (lt) * 2014-09-19 2024-01-10 Ferring Bv Praderio-vilio sindromo gydymo būdas
CN108351169B (zh) 2015-10-15 2022-01-28 康奈尔大学 蛋白酶体抑制剂及其用途
US11203613B2 (en) 2017-10-11 2021-12-21 Cornell University Peptidomimetic proteasome inhibitors
CN112969450B (zh) 2018-09-20 2023-05-30 阿卡蒂亚药品公司 卡贝缩宫素药物产品及用于制备其的方法
WO2020061414A1 (en) 2018-09-20 2020-03-26 Levo Therapeutics, Inc. Stable intranasal formulations of carbetocin
WO2021126990A1 (en) * 2019-12-16 2021-06-24 The Scripps Research Institute Oxytocin derivatives with improved properties

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009233429B2 (en) 2008-03-31 2014-02-13 Ferring B.V. Oxytocin analogues
TWI463990B (zh) * 2009-09-21 2014-12-11 Ferring Bv 催產素受體促進劑
US9119805B2 (en) * 2009-10-01 2015-09-01 The University Of Sydney Therapy and prevention of problem drinking
MY176398A (en) 2012-12-21 2020-08-05 Hoffmann La Roche Peptides as oxytocin agonists

Also Published As

Publication number Publication date
AU2013363768B2 (en) 2016-02-04
EA026687B1 (ru) 2017-05-31
NZ708175A (en) 2020-06-26
TW201429994A (zh) 2014-08-01
PE20151446A1 (es) 2015-09-28
MX2015007365A (es) 2015-10-14
PL2935312T3 (pl) 2018-12-31
PH12015501145B1 (en) 2015-08-10
CR20150271A (es) 2015-08-28
HUE039848T2 (hu) 2019-02-28
HRP20181569T1 (hr) 2018-11-30
CA2895150C (en) 2019-11-26
CN104870466B (zh) 2018-05-18
US9868766B2 (en) 2018-01-16
SI2935312T1 (sl) 2018-11-30
HK1208477A1 (zh) 2016-03-04
AU2013363768A1 (en) 2015-06-04
EP2935312B1 (en) 2018-08-08
EA201591078A1 (ru) 2015-10-30
JP6067878B2 (ja) 2017-01-25
IL239519A (en) 2017-06-29
PT2935312T (pt) 2018-10-26
KR101819804B1 (ko) 2018-01-17
UA119034C2 (uk) 2019-04-25
EP2935312A1 (en) 2015-10-28
ES2690317T3 (es) 2018-11-20
ZA201504186B (en) 2016-04-28
MX358684B (es) 2018-08-31
CL2015001724A1 (es) 2015-10-16
US20150284434A1 (en) 2015-10-08
AR094225A1 (es) 2015-07-22
IL239519A0 (en) 2015-08-31
WO2014095773A1 (en) 2014-06-26
BR112015014010A2 (pt) 2017-07-11
RS57690B1 (sr) 2018-11-30
TWI558726B (zh) 2016-11-21
KR20150085845A (ko) 2015-07-24
JP2016503044A (ja) 2016-02-01
CA2895150A1 (en) 2014-06-26
CN104870466A (zh) 2015-08-26
DK2935312T3 (en) 2018-10-22
MY176398A (en) 2020-08-05
MA38272A1 (fr) 2017-07-31
LT2935312T (lt) 2018-10-25
PH12015501145A1 (en) 2015-08-10

Similar Documents

Publication Publication Date Title
HRP20181569T1 (hr) Peptidi kao agonisti oksitocina
EP2857033A4 (en) SKIN-PUNKING PEPTIDE
HK1204797A1 (zh) 新穎的抗- 抗體
EP2812347A4 (en) AUTOPHAGIA-INDUCING PEPTIDE
EP2848687A4 (en) NOVEL EXPRESSION VECTOR
HK1211486A1 (zh) 新用途
GB201218813D0 (en) Antimicrobial peptides
HK1209138A1 (en) Peptides
GB201220119D0 (en) Vector
EP2865686A4 (en) EGFR-BINDING PEPTIDE
GB201200555D0 (en) Peptide
GB201204868D0 (en) Peptides
GB201223114D0 (en) Novel peptide
GB201205795D0 (en) Vector
GB201201720D0 (en) Novel combinations
PT2891663T (pt) Péptidos derivados de psf1
HK1201752A1 (zh) 鏈格孢屬的肽
GB201214413D0 (en) Festivalstand (festistand)
GB201304493D0 (en) Not published
GB201220328D0 (en) Peptides
GB201211740D0 (en) Peptides
GB201207895D0 (en) Peptides
GB201200509D0 (en) Peptides
GB201221414D0 (en) Trans-locating peptide
GB201200624D0 (en) Peptide